ANVS Annovis Bio
- 7.400
- -0.250-3.27%
Annovis Bio News
Buy Rating Maintained for Annovis Bio Ahead of Key Parkinson's Drug Trial Results
HC Wainwright & Co. : The Annovis Bio (ANVS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $30.00 to $23.00.
Annovis Bio Analyst Ratings
HC Wainwright & Co. Maintains Buy on Annovis Bio, Lowers Price Target to $23
Buy Rating Reaffirmed for Annovis Bio Amid Positive Prospects for Parkinson's Treatment
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
HC Wainwright & Co. : The Annovis Bio (ANVS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $30.00.
Annovis Bio Analyst Ratings
Annovis Bio Analyst Ratings
Buy Rating Reiterated for Annovis Bio Amid Anticipated Positive Trial Results for Alzheimer's and Parkinson's Treatments
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)
Analysts Are Bullish on These Healthcare Stocks: Insulet (PODD), Annovis Bio (ANVS)
Analysts Are Bullish on Top Healthcare Stocks: Femasys (FEMY), BioNTech SE (BNTX)
Annovis Bio Analyst Ratings
Annovis Bio Stock Downgraded to Hold With $9 Price Target
Annovis Bio Analyst Ratings
Maintaining Hold on Annovis Bio Amid Phase 3 Parkinson's Trial Concerns and Financial Uncertainties
Buy Rating Justified for Annovis Bio Amidst Promising Buntanetap Clinical Trials and Strong Commercial Prospects
Analysts Are Bullish on These Healthcare Stocks: Annovis Bio (ANVS), Alnylam Pharma (ALNY)
Buy Rating on Annovis Bio Amid Anticipated Positive Outcomes for Buntanetap in AD and PD Trials
Analysis
Price Target
No Data
